Genmab A/S Completes Successful Share Buy-back Program
Company Announcement
Genmab A/S (NASDAQ: GMAB) has proudly announced the successful completion of its share buy-back program, which came to a close on June 26, 2025. Initially launched in March, the program aimed to repurchase up to 2.2 million shares as part of a strategic initiative to reduce the company's capital while honoring commitments under the Restricted Stock Unit program.
Despite an initial estimate for the program's completion by July, activities continued efficiently, and shareholders were informed of varying transactions that took place between June 23, 2025, and June 26, 2025.
Detailed Transactions Under the Share Buy-back Program
Throughout the program, Genmab reported a total of 118,789 shares acquired, amounting to a value exceeding 157 million DKK. Each transaction showcased the commitment of Genmab to strengthen shareholder equity. The transactions were executed across various trading platforms, including XCSE, BCXE, AQEU, and TQEX, with comprehensive transaction details outlined in the public announcement.
The buy-backs were distributed as follows:
- On June 23, 2025, a total of 100 shares were purchased on the XCSE platform.
- On June 24, the company executed total share transactions of 26,129 shares.
- June 25 saw 45,961 shares acquired across multiple platforms.
- Finally, on June 26, 46,599 shares were bought back to conclude the program.
As a result of these transactions, Genmab retained about 2,651,727 shares as treasury shares, constituting 4.13% of the overall share capital and voting rights. This demonstrates Genmab's robust response to optimizing capital distribution and enhancing long-term value for its shareholders.
Compliance with Regulations
The share buy-back program was conducted under strict adherence to Regulation (EU) No. 596/2014, also known as the Market Abuse Regulation (MAR), along with the Commission Delegated Regulation (EU) 2016/1052 recognized as the Safe Harbour Regulation. This regulatory framework ensures transparency and fairness in share repurchase activities, providing reassurance to both investors and stakeholders.
For those interested in further details, they are available in Genmab's announcement dated March 25, 2025, outlining the parameters and objectives of the share buy-back program in a comprehensive format.
Genmab's Vision and Commitment to Innovation
Genmab is driven by a relentless commitment to innovation and improvement in patient care through biotechnology. Its focus lies in developing differentiated antibody therapeutics aimed at treating some of the most challenging diseases, particularly cancer.
With a legacy spanning over 25 years, Genmab's dedicated team has been at the forefront of ingenuity, creating next-generation antibody platforms and utilizing advanced quantitative and data sciences. The company envisions transforming patient lives through innovative therapeutic solutions, as seen in its proprietary pipeline featuring bispecific T-cell engagers and next-generation immune checkpoint modulators.
Looking forward to 2030, Genmab aims to deliver remarkable antibody medicines that can alter the course of treatment for patients, further solidifying its status as a pioneering company in the biotechnology landscape.
Contact Information for Further Inquiries
For more insights or inquiries regarding the share buy-back program or Genmab’s innovative initiatives, individuals can reach out to:
Contact:
Marisol Peron, Senior Vice President, Global Communications & Corporate Affairs
T: +1 609 524 0065; E: mmp@genmab.com
Andrew Carlsen, Vice President, Head of Investor Relations
T: +45 3377 9558; E: acn@genmab.com
Frequently Asked Questions
What was the purpose of Genmab's share buy-back program?
The program aimed to repurchase shares to reduce capital and honor commitments under the Restricted Stock Unit program.
How many shares were repurchased by Genmab?
A total of 118,789 shares were repurchased under the program.
What is Genmab's core focus as a biotechnology company?
Genmab focuses on developing innovative antibody therapeutics, particularly in the field of oncology.
Which regulatory frameworks guided the share buy-back program?
The program was conducted in line with Regulation (EU) No. 596/2014 and Commission Delegated Regulation (EU) 2016/1052.
How can I get more information about Genmab?
For further inquiries, you can contact Genmab's communications and investor relations teams via listed email addresses.
